Palvella therapeutics, inc.PVLA.US Overview

US StockHealthcare

(No presentation for PVLA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

PVLA Overall Performance

PVLA AI Analysis & Strategy

PVLA Recent Performance

-0.84%

Palvella therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

PVLA PowerScanner

PVLA Key Information

PVLA Valuation Metrics

PVLA Earnings Table

PVLA Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.